Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous CD40-activated acute lymphoblastic leukemia cell vaccine (Dana-Farber Cancer Institute)
- Development stage
- Discontinued
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Autologous CD40-activated acute lymphoblastic leukemia cell vaccine is an experimental cell-based immunotherapy developed by the Dana-Farber Cancer Institute. The vaccine is produced by collecting a patient's own malignant B-lineage acute lymphoblastic leukemia (ALL) cells and stimulating them ex vivo with CD40 ligand (CD40L). This activation triggers the leukemia cells to upregulate MHC and costimulatory molecules (such as CD80 and CD86), effectively converting the tumor cells into potent antigen-presenting cells (APCs). When these modified cells are re-administered to the patient, they are designed to present a broad array of patient-specific leukemia antigens to the endogenous immune system, thereby priming and expanding leukemia-specific T-cells to target and eliminate residual cancer cells.
- Other names
- CD40-activated ALL cell vaccineCD-40-activated ALL cell vaccineCD 40-activated ALL cell vaccineAutologous CD40-activated ALL vaccineCD 40CD40CD-40
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on Autologous CD40-activated acute lymphoblastic leukemia cell vaccine (Dana-Farber Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous CD40-activated acute lymphoblastic leukemia cell vaccine (Dana-Farber Cancer Institute).